Massachusetts has quietly turned into the country’s pressure-release valve for abortion care in the post-Dobbs era. State data show abortions in the commonwealth roughly doubled from 2023 to 2024, driven by a surge in telehealth prescriptions and a wave of patients traveling in from states with bans or tight restrictions. Along the way, the profile of who is getting care here has flipped, with non-residents now making up a growing share of procedures.
According to The Boston Globe, Massachusetts Department of Public Health figures show 49,450 abortions in 2024, up from 24,355 in 2023, a roughly 103 percent jump. Telehealth accounted for about 30,900 of those cases, or around 62 percent, in 2024, compared with 5,745 telehealth abortions the year before.
How telehealth and shield laws expanded access
Clinicians and researchers say the spike is largely about how care is delivered. Providers licensed and practicing in shield-law states began prescribing mifepristone via telehealth and mailing medications to patients in states where in-person care is severely limited or banned. A national report from Society of Family Planning documented a steep rise in clinician-provided telehealth abortions beginning in mid-2023, while an academic analysis of the Massachusetts Medication Abortion Access Project (MAP) describes an asynchronous, pay-what-you-can telemedicine model that reached patients across dozens of states.
Out-of-state patients now outnumber residents
The same state figures highlighted by The Boston Globe show just how much the patient mix has shifted. Of the 49,450 abortions in 2024, 27,836 involved out-of-state patients, while 21,407 were Massachusetts residents. That marks a reversal from 2023, when in-state residents were still the majority. Providers say many of those newer patients are traveling from states with near total bans or tight restrictions, often combining limited travel with telehealth referrals to complete their care.
Law and policy that made this possible
Clinicians credit Massachusetts’ Shield Law, formally An Act Expanding Protections for Reproductive and Gender-Affirming Care, along with follow-up Department of Public Health regulations, for lowering the legal risk for prescribers and pharmacies. State guidance limits cooperation with out-of-state investigations and sets out licensing protections that providers say have been crucial for sustaining telehealth prescribing and mail delivery of medication abortion. The protections are spelled out in official materials from Mass.gov.
Medication abortions are now the norm
National research and provider surveys indicate that medication abortion has become the dominant method of termination, and Massachusetts is firmly in that trend. The Guttmacher Institute has documented that medication abortions now make up the majority of clinician-provided abortions in recent counts, a shift that has intensified debates over how mifepristone is regulated and how telehealth access is enforced.
What providers and advocates say next
Local providers say demand is likely to keep climbing for a while, yet they describe the landscape as fragile. Shield-law protections have allowed access to expand, but cross-state legal fights and renewed scrutiny of the abortion pill could still change how care is delivered. As The Guardian reported, MAP co-founder Dr. Angel Foster has warned that the current surge will not go on forever, saying, "There will be a point where growth stops. There's a finite number of people who have an abortion each year." At the same time, lawyers and state officials are tracking lawsuits from other states that are testing whether shield-law models and mail-order medication can hold up under legal pressure.
For Massachusetts residents, the fallout is mixed. The state has strengthened protections and expanded capacity, yet providers and advocates note that national policy shifts and court decisions could still reshape how and where people access care. Officials and clinics say they are bracing for continued demand while keeping close watch on evolving legal risks and on the supply chain for medication abortion.
